A2JMW6 Cytori Therapeutics Inc.

ReSPECT Glioblastoma Clinical Trial Data to be Presented at 2020 Society for Neuro-Oncology Annual Meeting

ReSPECT Glioblastoma Clinical Trial Data to be Presented at 2020 Society for Neuro-Oncology Annual Meeting
EN
01/10/2020

Underlying

A2JMW6Cytori Therapeutics Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cytori Therapeutics Inc.

 PRESS RELEASE
Free
A2JMW6 Cytori Therapeu...

Plus Therapeutics to Participate in Upcoming January Conferences

Plus Therapeutics to Participate in Upcoming January Conferences AUSTIN, Texas, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: ) (the “Company”), a clinical-stage company focused on making a positive impact on patients’ lives, today announced that Marc Hedrick, M.D., President and Chief Executive Officer of Plus Therapeutics, will present at three upcoming virtual conferences. EventH.C. Wainwright BioConnect ConferenceDateJanuary 11-14, 2021TimePresentation available on demand January 11-14, 2021  EventBiotech Showcase 2021DateJanuary 11-15, 2021  EventICR Conference ...

January 5, 2021 1 EN
 PRESS RELEASE
Free
A2JMW6 Cytori Therapeu...

Plus Therapeutics Completes Sixth Dosing Cohort in ReSPECT™ Glioblasto...

Plus Therapeutics Completes Sixth Dosing Cohort in ReSPECT™ Glioblastoma Trial AUSTIN, Texas, Dec. 15, 2020 (GLOBE NEWSWIRE) -- (Nasdaq: ) (the “Company”), a clinical-stage pharmaceutical company developing novel, targeted and personalized therapies for rare and difficult to treat cancers, today announced completion of the sixth dosing cohort in the ReSPECT™ Phase 1 clinical trial evaluating the Company’s lead investigational asset, Rhenium NanoLiposome (RNL™), in patients with recurrent glioblastoma (GBM). The sixth cohort of the ReSPECT trial included an increase in both the RNL drug ...

December 15, 2020 1 EN
 PRESS RELEASE
Free
A2JMW6 Cytori Therapeu...

Plus Therapeutics to Present at 13th Annual LD Micro Main Event Confer...

Plus Therapeutics to Present at 13th Annual LD Micro Main Event Conference AUSTIN, Texas, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: ) (the “Company”), a clinical-stage company focused on making a positive impact on patients’ lives, today announced that Marc Hedrick, M.D., President and Chief Executive Officer of Plus Therapeutics, has been invited to present a Company overview during the 13th Annual LD Micro Main Event Conference on Monday, December 14th at 10:40 a.m. ET. For conference participants, a live webcast of the presentation can be found by visiting the...

December 8, 2020 1 EN
 PRESS RELEASE
Free
A2JMW6 Cytori Therapeu...

Plus Therapeutics Expands ReSPECT™ Clinical Trial to MD Anderson Cance...

Plus Therapeutics Expands ReSPECT™ Clinical Trial to MD Anderson Cancer Center AUSTIN, Texas., Dec. 01, 2020 (GLOBE NEWSWIRE) -- (Nasdaq: ) (the “Company”), a clinical-stage pharmaceutical company developing novel, targeted and personalized therapies for rare and difficult to treat cancers, today announced that the University of Texas MD Anderson Cancer Center is now an active clinical trial site in its ongoing ReSPECT™ Phase 1 clinical trial, currently supported by the National Cancer Institute (NCI). ReSPECT is a multi-center, dose-finding study evaluating the Company’s lead investigat...

December 1, 2020 1 EN
 PRESS RELEASE
Free
A2JMW6 Cytori Therapeu...

Plus Therapeutics Announces Positive Interim Data from ReSPECT™ Phase ...

Plus Therapeutics Announces Positive Interim Data from ReSPECT™ Phase 1 Clinical Trial in Recurrent Glioblastoma Investigational drug RNL™ delivers up to fifteen times the absorbed dose of radiation compared to standard external beam radiation therapy RNL was generally well-tolerated with no dose-limiting toxicities observed Company management and principal investigator of ReSPECT to discuss interim data during webinar scheduled for Thursday, November 19, 2020 at 4:30 - 5:30 p.m. ET AUSTIN, Texas, Nov. 19, 2020 (GLOBE NEWSWIRE) -- (Nasdaq: ) (the “Company”), a clinical-stage pharmaceu...

November 19, 2020 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch